Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Armstrong AJ, et al. Among authors: dahut wl. Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. Ann Oncol. 2018. PMID: 29088323 Free PMC article. No abstract available.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Bubley GJ, et al. J Clin Oncol. 1999 Nov;17(11):3461-7. doi: 10.1200/JCO.1999.17.11.3461. J Clin Oncol. 1999. PMID: 10550143
Anti-angiogenic therapy in renal cell cancer.
Srinivasan R, Armstrong AJ, Dahut W, George DJ. Srinivasan R, et al. BJU Int. 2007 May;99(5 Pt B):1296-300. doi: 10.1111/j.1464-410X.2007.06834.x. BJU Int. 2007. PMID: 17441927 Review.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O; Prostate Specific Antigen Working Group. Arlen PM, et al. Among authors: dahut wl. J Urol. 2008 Jun;179(6):2181-5; discussion 2185-6. doi: 10.1016/j.juro.2008.01.099. Epub 2008 Apr 18. J Urol. 2008. PMID: 18423743 Free PMC article.
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology Health Services Committee; American Urological Association Practice Guidelines Committee. Kramer BS, et al. J Clin Oncol. 2009 Mar 20;27(9):1502-16. doi: 10.1200/JCO.2008.16.9599. Epub 2009 Feb 24. J Clin Oncol. 2009. PMID: 19252137 Free PMC article. Review.
Challenges in clinical prostate cancer: role of imaging.
Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group. Kelloff GJ, et al. AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579. AJR Am J Roentgenol. 2009. PMID: 19457806 Free PMC article.
Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
Lin C, Bradshaw T, Perk T, Harmon S, Eickhoff J, Jallow N, Choyke PL, Dahut WL, Larson S, Humm JL, Perlman S, Apolo AB, Morris MJ, Liu G, Jeraj R. Lin C, et al. Among authors: dahut wl. J Nucl Med. 2016 Dec;57(12):1872-1879. doi: 10.2967/jnumed.116.177295. Epub 2016 Jul 21. J Nucl Med. 2016. PMID: 27445292 Free PMC article. Clinical Trial.
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL. Heery CR, et al. Among authors: dahut wl. Oncotarget. 2016 Oct 18;7(42):69014-69023. doi: 10.18632/oncotarget.10883. Oncotarget. 2016. PMID: 27486817 Free PMC article. Clinical Trial.
Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.
Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R. Harmon SA, et al. Among authors: dahut wl. J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654366 Free PMC article. Clinical Trial.
Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer.
Weisman AJ, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Humm JL, Apolo AB, Larson SM, Morris MJ, Perlman SB, Liu G, Jeraj R. Weisman AJ, et al. Among authors: dahut wl. Prostate Cancer Prostatic Dis. 2019 May;22(2):324-330. doi: 10.1038/s41391-018-0110-5. Epub 2018 Nov 9. Prostate Cancer Prostatic Dis. 2019. PMID: 30413807 Free PMC article.
248 results